Skip to main content
Journal ArticleOPEN ACCESS

Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)

  • Le Cesne A
  • Blay J
  • Cupissol D
  • et al.
Annals of Oncology (2016) 27 vi483
DOI: 10.1093/annonc/mdw388.02
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background Trabectedin (T) has demonstrated single-agent activity in patients (pts) with pretreated ASTS and was approved in 2007 in Europe in this indication. With the exception of a …

Cite

CITATION STYLE

APA

Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., … Foulon, S. (2016). Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS). Annals of Oncology, 27, vi483. https://doi.org/10.1093/annonc/mdw388.02

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free